Causes of death
| . | ATG . | Alemtuzumab . | T cell–replete . | P . |
|---|---|---|---|---|
| No. of deaths | 98 | 59 | 210 | |
| Primary disease, n (%) | 41 (42) | 25 (42) | 91 (43) | .97 |
| GVHD, n (%) | 10 (10) | 6 (10) | 23 (11) | .97 |
| Infection, n (%) | 10 (10) | 13 (22) | 27 (13) | .10 |
| IPN/ARDS, n (%) | 17 (17) | 7 (12) | 14 (7) | .02 |
| Organ failure, n (%) | 15 (15) | 7 (12) | 34 (16) | .71 |
| Other causes, n (%) | 5 (5) | 1 (2) | 21 (10) | .06 |
| . | ATG . | Alemtuzumab . | T cell–replete . | P . |
|---|---|---|---|---|
| No. of deaths | 98 | 59 | 210 | |
| Primary disease, n (%) | 41 (42) | 25 (42) | 91 (43) | .97 |
| GVHD, n (%) | 10 (10) | 6 (10) | 23 (11) | .97 |
| Infection, n (%) | 10 (10) | 13 (22) | 27 (13) | .10 |
| IPN/ARDS, n (%) | 17 (17) | 7 (12) | 14 (7) | .02 |
| Organ failure, n (%) | 15 (15) | 7 (12) | 34 (16) | .71 |
| Other causes, n (%) | 5 (5) | 1 (2) | 21 (10) | .06 |
IPN indicates interstitial pneumonitis; and ARDS, adult respiratory distress syndrome.